Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation]

[Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Abstract Text:

    dong-lin yangDong-lin Yang,ming-zhe hanMing-zhe Han,si-zhou fengSi-zhou Feng,mei wangMei Wang,de-hui zouDe-hui Zou,jia-lin weiJia-lin Wei,zhang-song yanZhang-song Yan,si-yong zhouSi-yong Zhou,qing-guo liuQing-guo Liu,er-lie jiangEr-lie Jiang,yong huangYong Huang,he-hua wangHe-hua Wang,zheng zhouZheng Zhou,wen-jing zhaiWen-jing Zhai,wen-wei yanWen-wei Yan,zhong-chao hanZhong-chao Han,

    OBJECTIVE: To evaluate the efficacy of second allogeneic hematopoietic stem cell transplantation (allo-HSCT) for treatment of leukemia relapsed after first allo-HSCT. METHODS: Nine patients with relapsed acute leukemia (5 AML, 4 ALL) and one with chronic myelogenous leukemia (CML) who showed cytogenetic relapse after first allo-HSCT received second allo-HSCT. The median relapse time from the first allo-HSCT was 141 days. Conditioning regimens for second allo-HSCT were combination chemotherapy based on moderate-dose Ara-C (n = 5), Bu (n = 3), conventional-dose Ara-C (n = 1) and Flud/Mel (n = 1). Prophylaxis for acute graft-versus-host disease (aGVHD) were CsA alone (n = 2), CsA/MTX (n = 1), FK506 (n = 1), and no prophylaxis in 6. The median number of peripheral blood mononuclear cells transfused was 6.1 x 10(8)/kg. RESULTS: Eight cases were evaluable. All of them were engrafted and 7 developed aGVHD (grade I 4, grade II 3). The median time for absolute neutrophil count (ANC) > 0.5 x 10(9)/L and platelets > 20 x 10(9)/L were 11 and 12 days, respectively. Five cases developed localized chronic GVHD. Of all the 10 cases received second allo-HSCT, 8 died from interstitial pneumonia (n = 2), multiple-organ failure (n = 1), sepsis (n = 1), fungous pneumonia (n = 1), and leukemia relapse (n = 3), and 2 survived without leukemia for +986 and +1913 days, respectively. The leukemia free survival, transplantation related mortality and relapse rate at 2 year were 20%, 50% and 30%, respectively. CONCLUSION: Second allo-HSCT is a therapeutic alternative for selected patients with relapsed leukemia after first allo-HSCT.

    [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Publishing Authors By Initials

    dl yangDL Yang,mz hanMZ Han,sz fengSZ Feng,m wangM Wang,dh zouDH Zou,jl weiJL Wei,zs yanZS Yan,sy zhouSY Zhou,qg liuQG Liu,el jiangEL Jiang,y huangY Huang,hh wangHH Wang,z zhouZ Zhou,wj zhaiWJ Zhai,ww yanWW Yan,zc hanZC Han,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zaz

    VOLUME: 25

    Page Numbers: 285-9

    Journal Abbreviation: Zhonghua Xue Ye Xue Za Zhi

    ISSN: 0253-2727

    DAY: 8

    MONTH: May

    YEAR: 2004

    [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Information

    Number of References:

    LANGUAGE: chi

    NlmUniqueID: 8212398

    [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation] Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for [Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation]

    AFFILIATION: Institute of Hematology and Blood Diseases Hospital, CAMS and PUMC, Tianjin 300020, China.

    Country: China

    China Research PublicationChina Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Zhonghua Xue Ye Xue Za Zhi

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Second allogeneic transplant for leukemia relapsed after first allogeneic transplantation Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News